• US therapeutic: $463.0M (+7% YoY, +7% QoQ*) • US cosmetic: $271.8M (+6% YoY, +14% QoQ*) -- US total: $734.8M (63% therapeutic; 37% cosmetic) was 72% of worldwide total
• Ex-US therapeutic: $102.5M (+9% YoY, +9% QoQ*) • Ex-US cosmetic: $182.9M (+20% YoY, +10% QoQ*) -- Ex-US total: $285.4M (36% therapeutic; 64% cosmetic) was 28% of worldwide total
*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.